<DOC>
	<DOCNO>NCT00897702</DOCNO>
	<brief_summary>The purpose study learn certain drug stop work patients.In lab study , tumor become resistant several way . Specific molecule seem change may therapy stop work . However , know molecule change patient . This study do see change . If learn patient become resistant , may able offer well treatment future .</brief_summary>
	<brief_title>Molecular Mechanisms Clinical Resistance Targeted Therapy Among Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>All patient : Diagnosed progressive , recurrent metastatic HER2+ ER+ breast cancer . Cohort 1 Patients previously receive treatment antiHER2 therapy ( include trastuzumab , pertuzumab , TDM1 , lapatinib ) part adjuvant chemotherapy progressive recurrent breast cancer , patient previously ( currently ) receive antiHER2 therapy part regimen metastatic breast cancer subsequently experience . Evidence disease progression recurrence prior therapy ( e.g . radiologic progression RECIST criteria new metastasis ) . Prior tumor biopsy ( may original ) define HER2+ amplification FISH ( &gt; 1.9 gene copy number ) IHC 3+ . Cohort 2 Patients previously receive treatment hormonal therapy ( include tamoxifen , toremifene , raloxifene , anastrozole , letrozole , exemestane , fulvestrant , ARN810 ) part adjuvant therapy progressive recurrent breast cancer patient previously ( currently ) receive hormonal therapy part regimen metastatic breast cancer subsequently experience evidence disease progression . Cohort 3 Patients eligible Cohorts 1 2 , previously receive treatment kind breast cancer . Patients unable consent biopsy . Patients repeat biopsy would medically unsafe</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>